Zambon is one of the world's leading pharmaceutical and chemical multinationals, earning a strong reputation over the years for its high-quality products, flexibility and customer service.
Thanks to its new "Open Innovation" approach, Zambon pairs its internal research with the exploration of international scenarios, collaborating with Research Institutues, Technology Transfers, Start-ups and Biotec Companies.
2 march 2015
Xadago® (safinamide) New Drug Application (NDA) Accepted for Filing by the U.S. Food and Drug Administration (FDA)
26 february 2015
Parkinson’s disease (PD): EU Commission approves Xadago® (safinamide) For mid-late stage PD patients
19 december 2014
CHMP recommends Approval of XadagoTM (safinamide) to treat Parkinson's disease in the EU
Zambon Company S.p.A. - ©2015, All rights reserved
Switchboard: +39 02665241